136834-21-4

Basic information

• Product Name: Adenosine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-deoxy-2'-fluoro-
• Synonyms: Adenosine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-deoxy-2'-fluoro-;N6-benzoyl-2'-deoxy-2'-fluoro-5'-O-(4,4'-dimethoxytrityl)adenosine;N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-2'-fluoroadenosine;5'-O-DMT-N6-BENZOYL-2'-FLUORO-2'-DEOXYADENOSINE
• CAS NO: 136834-21-4
• Molecular Formula: C₃₈H₃₄FN₅O₆
• Molecular Weight: 675.7048632
• Mol File: 136834-21-4.mol

Chemical Properties

• Appearance: /
• Density: 1.35±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 7.87±0.43(Predicted)
• CAS DataBase Reference: Adenosine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-deoxy-2'-fluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: Adenosine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-deoxy-2'-fluoro-(136834-21-4)
• EPA Substance Registry System: Adenosine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-deoxy-2'-fluoro-(136834-21-4)

Safety Data

• Hazardous Substances Data: 136834-21-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Adenosine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-deoxy-2'-fluorois used as a nucleoside building block for the preparation of 3'',4''-oxetane nucleosides. The application reason is its potential anti-viral properties, particularly towards Hepatitis C. The unique molecular structure of Adenosine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-deoxy-2'-fluoro- may provide a new approach to developing effective treatments for this viral infection.
In addition to its use in the pharmaceutical industry, Adenosine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-deoxy-2'-fluoro- may also have potential applications in other fields, such as:
1. Chemical Research:
As a complex organic molecule, Adenosine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-deoxy-2'-fluorocould be used in chemical research to study the effects of its unique structure on various chemical reactions and interactions with other molecules.
2. Material Science:
The unique properties of Adenosine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-deoxy-2'-fluoro-, such as its modified adenosine structure and the presence of fluorine, may make it a candidate for the development of new materials with specific characteristics, such as improved stability or reactivity.
3. Diagnostics:
The modified adenosine structure could potentially be utilized in the development of diagnostic tools or tests, particularly in the field of molecular biology, where the detection and analysis of specific nucleosides and nucleotides are crucial.

Upstream product

• 136834-20-3 N-(9-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide 
• 136834-19-0 N⁶-benzoyl-9-<2-O-(trifluoromethylsulfonyl)-3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl>adenine 
• 146954-64-5 N⁶-benzoyl-2'-deoxy-2'-fluoro-3',5'-di-O-tetrahydropyran-2-yladenosine 
• 136834-18-9 N⁶-benzoyl-9-(3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl)adenine 
• 79896-97-2 N6-benzoyl-9-β-D-arabinofuranosyladenine 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 98-88-4 benzoyl chloride 
• 20187-82-0 2'-fluorodeoxyadenosine 

Downstream Products

• 136834-22-5 N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-3-fluoro-tetrahydrofuran-2-yl]purin-6-yl]benzamide 

Relevant articles and documents

SALTS OF COMPOUNDS AND CRYSTALS THEREOF

The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34λ5,39λ5-diphosphaoctacyclo[28.6.4.13,36/sup

Cyclic dinucleotide analogues, pharmaceutical composition of analogues and applications of analogues and pharmaceutical composition

The invention discloses cyclic dinucleotide analogues, a pharmaceutical composition of the analogues and applications of the analogues and the pharmaceutical composition. The cyclic dinucleotide analogs (I), an isomer, prodrug, stable isotope derivative or pharmaceutically acceptable salt of the analogs have a structure shown in the specification. The cyclic dinucleotide analogs provided by the invention can be used as regulators of stimulator of interferon genes (STIG) and related signaling pathways, and can effectively treat and/or alleviate multiple types of diseases, including but not limited to malignant tumors, inflammation, autoimmune diseases and infectious diseases; and in addition, the STING regulators can also be used as vaccine adjuvants.

CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS

The present disclosure relates to a compound of formulae (I) or (II), or a pharmaceutically acceptable salt, a solvate, a hydrate thereof, a pharmaceutical composition comprising a compound of formulae (I) or (II), and use thereof, wherein various Markush

Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)

Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

CYCLIC DI-NUCLEOTIDES COMPOUNDS FOR THE TREATMENT OF CANCER

Provided herein are compounds useful for the treatment of cancer.

CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING

Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.

CYCLIC DINUCLEOTIDES AS STING AGONISTS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B

Synthesis and anti-HCV activity of 3′,4′-oxetane nucleosides

Hepatitis C virus afflicts approximately 180 million people worldwide and currently there are no direct acting antiviral agents available to treat this disease. Our first generation nucleoside HCV inhibitor, RG7128 has already established proof-of-concept

Antisense modulation of polo-like kinase expression

Antisense compounds, compositions and methods are provided for modulating the expression of polo-like kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding polo-like kinase. Methods of using these compounds for modulation of polo-like kinase expression and for treatment of diseases associated with expression of polo-like kinase are provided.

Antisense modulation of perilipin expression

Antisense compounds, compositions and methods are provided for modulating the expression of perilipin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding perilipin. Methods of using these compounds for modulation of perilipin expression and for treatment of diseases associated with expression of perilipin are provided.